% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Franceschi:181119,
      author       = {E. Franceschi and C. Giannini and J. Furtner and K.
                      Pajtler$^*$ and S. Asioli and R. Guzman and C. Seidel and L.
                      Gatto and P. Hau},
      title        = {{A}dult {M}edulloblastoma: {U}pdates on {C}urrent
                      {M}anagement and {F}uture {P}erspectives.},
      journal      = {Cancers},
      volume       = {14},
      number       = {15},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2022-01788},
      pages        = {3708},
      year         = {2022},
      abstract     = {Medulloblastoma (MB) is a malignant embryonal tumor of the
                      posterior fossa belonging to the family of primitive
                      neuro-ectodermic tumors (PNET). MB generally occurs in
                      pediatric age, but in $14-30\%$ of cases, it affects the
                      adults, mostly below the age of 40, with an incidence of 0.6
                      per million per year, representing about $0.4-1\%$ of tumors
                      of the nervous system in adults. Unlike pediatric MB, robust
                      prospective trials are scarce for the post-puberal
                      population, due to the low incidence of MB in adolescent and
                      young adults. Thus, current MB treatments for older patients
                      are largely extrapolated from the pediatric experience, but
                      the transferability and applicability of these paradigms to
                      adults remain an open question. Adult MB is distinct from MB
                      in children from a molecular and clinical perspective. Here,
                      we review the management of adult MB, reporting the recent
                      published literature focusing on the effectiveness of
                      upfront chemotherapy, the development of targeted therapies,
                      and the potential role of a reduced dose of radiotherapy in
                      treating this disease.},
      subtyp        = {Review Article},
      keywords     = {SHH inhibitors (Other) / SHH pathway (Other) / chemotherapy
                      (Other) / medulloblastoma (Other) / neurosurgery (Other) /
                      radiotherapy (Other) / sonic hedgehog (SHH) (Other) /
                      sonidegib (Other) / targeted therapy (Other) / vismodegib
                      (Other)},
      cin          = {B062 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:35954372},
      doi          = {10.3390/cancers14153708},
      url          = {https://inrepo02.dkfz.de/record/181119},
}